Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Page 1
Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy.
Bommier C, Zucca E, Chevret S, Conconi A, Nowakowski G, Maurer MJ, Cerhan JR, Thieblemont C, Lambert J. Bommier C, et al. Among authors: chevret s. Blood. 2024 Feb 1;143(5):422-428. doi: 10.1182/blood.2023020984. Blood. 2024. PMID: 37801707
We found that TTCR24 predicted 95% and that CR24 mediated 90% of the treatment effect on long-term PFS. Therefore, TTCR24 and CR24 could be used in clinical trials as informative and valid early indicators of treatment effect on PFS. ...
We found that TTCR24 predicted 95% and that CR24 mediated 90% of the treatment effect on long-term PFS. Therefore, TTCR24 and CR24 co …
Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial.
Chevret S, Bouadma L, Dupuis C, Burdet C, Timsit JF; COVIDICUS RCT group. Chevret S, et al. Ann Intensive Care. 2023 Aug 27;13(1):75. doi: 10.1186/s13613-023-01168-z. Ann Intensive Care. 2023. PMID: 37634234 Free PMC article.
TRIAL REGISTRATION: NCT04344730, date of registration April 14, 2020 ( https://clinicaltrials.gov/ct2/show/NCT04344730?term=NCT04344730&draw=2&rank=1 ); EudraCT: 2020-001457-43 ( https://www.clinicaltrialsregister.eu/ctr-search/search?...
TRIAL REGISTRATION: NCT04344730, date of registration April 14, 2020 ( https://clinicaltrials.gov/ct2/show/NCT04344730?term=NCT043447 …
Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
Guerrero A, Campo LD, Piscaglia F, Scheiner B, Han G, Violi F, Ferreira CN, Téllez L, Reiberger T, Basili S, Zamora J, Albillos A; Baveno Cooperation: an EASL consortium. Guerrero A, et al. J Hepatol. 2023 Jul;79(1):69-78. doi: 10.1016/j.jhep.2023.02.023. Epub 2023 Feb 28. J Hepatol. 2023. PMID: 36858157
According to our findings, portal vein thrombosis may identify a group of patients with cirrhosis that benefit from long-term anticoagulation....
According to our findings, portal vein thrombosis may identify a group of patients with cirrhosis that benefit from long-term anticoa …
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
Louvet A, Bourcier V, Archambeaud I, d'Alteroche L, Chaffaut C, Oberti F, Moreno C, Roulot D, Dao T, Moirand R, Duclos-Vallée JC, Goria O, Nguyen-Khac E, Pol S, Carbonell N, Gournay J, Elkrief L, Fouchard-Hubert I, Chevret S, Ganne-Carrié N; CIRRAL group. Louvet A, et al. Among authors: chevret s. J Hepatol. 2023 Mar;78(3):501-512. doi: 10.1016/j.jhep.2022.11.013. Epub 2022 Nov 22. J Hepatol. 2023. PMID: 36423805
BACKGROUND & AIMS: The harmful impact of heavy alcohol consumption and recurrence in patients with alcohol-related cirrhosis is long-established, although this is based on old studies. However, the drivers of long-term outcome still need to be clearly investigated. MET …
BACKGROUND & AIMS: The harmful impact of heavy alcohol consumption and recurrence in patients with alcohol-related cirrhosis is long-est …
Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.
Fodil S, Chevret S, Rouzaud C, Valade S, Rabian F, Mariotte E, Raffoux E, Itzykson R, Boissel N, Sébert M, Adès L, Zafrani L, Azoulay E, Lengliné E. Fodil S, et al. Among authors: chevret s. PLoS One. 2022 Jul 7;17(7):e0270744. doi: 10.1371/journal.pone.0270744. eCollection 2022. PLoS One. 2022. PMID: 35797337 Free PMC article.
Retrospective studies showed that several symptomatic measures might decrease early death rate but long-term data are scarce. We aimed to analyze whether the therapeutic measures carried out urgently at diagnosis may influence the outcome among HL AML patients having achie …
Retrospective studies showed that several symptomatic measures might decrease early death rate but long-term data are scarce. We aime …
Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort.
Pons M, Chevret S, Briot K, d'Agostino MA, Roux C, Dougados M, Molto A. Pons M, et al. Among authors: chevret s. RMD Open. 2022 Jan;8(1):e001846. doi: 10.1136/rmdopen-2021-001846. RMD Open. 2022. PMID: 35042728 Free PMC article.
OBJECTIVE: To evaluate long-term effectiveness of tumour necrosis factor inhibitor (TNFi) after a first switch, and their associated factors in an early axial spondyloarthritis (axSpA) population, considering time-varying prescription bias. METHODS: Observational prospecti …
OBJECTIVE: To evaluate long-term effectiveness of tumour necrosis factor inhibitor (TNFi) after a first switch, and their associated …
DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M, Biard L, Chevret S. Ursino M, et al. Among authors: chevret s. Biom J. 2022 Dec;64(8):1486-1497. doi: 10.1002/bimj.202000369. Epub 2021 Nov 2. Biom J. 2022. PMID: 34729815
Dose-finding clinical trials in oncology aim to determine the maximum tolerated dose (MTD) of a new drug, generally defined by the proportion of patients with short-term dose-limiting toxicities (DLTs). Model-based approaches for such phase I oncology trials have been wide …
Dose-finding clinical trials in oncology aim to determine the maximum tolerated dose (MTD) of a new drug, generally defined by the proportio …
Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.
Benattia A, Bugnet E, Walter-Petrich A, de Margerie-Mellon C, Meignin V, Seguin-Givelet A, Lorillon G, Chevret S, Tazi A. Benattia A, et al. Among authors: chevret s. Eur Respir J. 2022 May 26;59(5):2101017. doi: 10.1183/13993003.01017-2021. Print 2022 May. Eur Respir J. 2022. PMID: 34675043 Free article.
BACKGROUND: The long-term outcomes of adult pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, are largely unknown. ...Eight (5.1%) of the 157 patients with isolated PLCH developed extrapulmonary involvement. CONCLUSION: The long-term prognosis o …
BACKGROUND: The long-term outcomes of adult pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, are largely unknow …
Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital.
Vallet N, Chevret S, Feghoul L, Aguinaga L, Bondeelle L, Kaphan E, Bertinchamp R, Soret J, Villesuzanne C, De Castro N, Sebert M, Boutboul D, Lengline E, Tudesq JJ, Rabian F, Adès L, Xhaard A, Di Blasi R, Raffoux E, Galicier L, Le Goff J, Delaugerre C, Bergeron A, Harel S; Saint-Louis CORE group. Vallet N, et al. Among authors: chevret s. Blood Cancer J. 2021 Jul 14;11(7):129. doi: 10.1038/s41408-021-00512-5. Blood Cancer J. 2021. PMID: 34262018 Free PMC article. No abstract available.
Nutritional status, swallowing disorders, and respiratory prognosis in adult Duchenne muscular dystrophy patients.
Fayssoil A, Chaffaut C, Prigent H, Laforet P, Clair B, Orlikowski D, Ogna A, Chevret S, Meng P, Annane D, Lofaso F, Crenn P. Fayssoil A, et al. Among authors: chevret s. Pediatr Pulmonol. 2021 Jul;56(7):2146-2154. doi: 10.1002/ppul.25430. Epub 2021 May 3. Pediatr Pulmonol. 2021. PMID: 33939888
We assessed, in adult DMD with home mechanical ventilation (HMV) and cough assist device, its prevalence and the relationships with respiratory muscle strength and long-term respiratory prognosis. We reviewed the patients (n = 117, age 18-39 years [median 24]), followed in …
We assessed, in adult DMD with home mechanical ventilation (HMV) and cough assist device, its prevalence and the relationships with respirat …
68 results